Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$407.17
+0.6%		$361.29
$269.77
▼
$418.40
$219.37B0.412.74 million shs39,580 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,183.52
-0.7%		$1,157.76
$623.78
▼
$1,249.45
$1.11T0.513.13 million shs149,784 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.97
+2.2%		$46.96
$35.12
▼
$64.16
$209.86B0.7618.16 million shs1.27 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-0.73%+4.44%+9.98%+22.05%+42.22%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+1.84%+3.11%-3.36%+25.72%+59.73%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+3.20%-10.95%-7.45%-0.25%+1.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$407.17
+0.6%		$361.29
$269.77
▼
$418.40
$219.37B0.412.74 million shs39,580 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,183.52
-0.7%		$1,157.76
$623.78
▼
$1,249.45
$1.11T0.513.13 million shs149,784 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.97
+2.2%		$46.96
$35.12
▼
$64.16
$209.86B0.7618.16 million shs1.27 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-0.73%+4.44%+9.98%+22.05%+42.22%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+1.84%+3.11%-3.36%+25.72%+59.73%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+3.20%-10.95%-7.45%-0.25%+1.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.35
Hold$367.93-9.64% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,293.939.33% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.19
Hold$65.8140.13% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, and AMGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2026
Amgen Inc. stock logo
AMGN
Amgen
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$1,370.00 ➝ $1,376.00
8/6/2026
Amgen Inc. stock logo
AMGN
Amgen
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$335.00 ➝ $345.00
8/6/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$1,419.00
8/6/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform$47.00
8/6/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,280.00 ➝ $1,330.00
8/6/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$1,400.00
8/6/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,350.00 ➝ $1,410.00
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
8/5/2026
Amgen Inc. stock logo
AMGN
Amgen
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$385.00 ➝ $450.00
8/5/2026
Amgen Inc. stock logo
AMGN
Amgen
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$420.00 ➝ $440.00
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$36.75B5.98$33.76 per share12.06$21.66 per share18.80
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$79.67B13.99$25.43 per share46.54$28.07 per share42.16
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.48$4.94 per share9.50$6.58 per share7.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$14.3725.2617.044.1022.95%124.14%13.18%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$29.8039.4926.311.4133.53%103.84%24.63%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.0911.4914.324.0635.36%61.20%21.49%N/A

Latest LLY, NVO, and AMGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
6/30/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$0.9440N/A$0.72N/A$11.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.48%+8.27%70.15%14 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.58%+15.18%23.22%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.73%+21.74%42.79%N/A

Latest LLY, NVO, and AMGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.6%8/21/20268/21/20269/11/2026
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.63%8/14/20268/14/20269/10/2026
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.54%8/17/20268/17/20268/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.01
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500539.71 million535.12 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

The Week in Numbers: BP's huge profit, Toyota moves fast
 |  finance.yahoo.comhttps://finance.yahoo.com/video/week-numbers-bps-huge-profit-104138978.html
Empowered Funds LLC Trims Holdings in Novo Nordisk A/S $NVO
August 7 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-trims-holdings-in-novo-nordisk-as-nvo-2026-08-07/
Novo Nordisk CEO resets expectations for Wegovy's explosive growth
August 7 at 1:14 AM  |  thestreet.comhttps://www.thestreet.com/investing/stocks/nvo-novo-nordisk-doustdar-resets-expectations-wegovy-pill-growth-after-sales-miss
Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ...
August 6 at 8:14 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lexicon-pharmaceuticals-inc-lxrx-q2-231843876.html
Novo Nordisk A/S (NYSE:NVO) Declares $0.58 Dividend
August 6 at 1:49 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novo-nordisk-as-nysenvo-declares-058-dividend-2026-08-06/
Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
August 6 at 1:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4931976-novo-nordisk-the-market-has-lost-its-mind-too-cheap-to-ignore
NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
August 6 at 11:04 AM  |  zacks.comhttps://www.zacks.com/stock/news/2969962/nvo-q2-earnings-call-centers-on-wegovy-pill-and-outlook-lift?cid=cs-stocknewsapi-ft-analyst_blog_plus|earnings_call_takeaways-2969962
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
August 6 at 10:11 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lexicon-pharmaceuticals-reports-second-quarter-113000634.html
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
August 6 at 9:45 AM  |  cnbc.comhttps://www.cnbc.com/2026/08/06/eli-lilly-novo-nordisk-earnings-glp1-market.html
Novo Nordisk A/S (NYSE:NVO) Given Average Recommendation of "Hold" by Brokerages
August 6 at 6:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novo-nordisk-as-nysenvo-given-average-recommendation-of-hold-by-brokerages-2026-08-06/
How Novo Nordisk's CEO Says He Is Shifting the Company's Perspective
August 6 at 5:49 AM  |  wsj.comhttps://www.wsj.com/business/how-novo-nordisks-ceo-says-he-is-shifting-the-companys-perspective-44451656
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
August 6 at 5:10 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-trading-novo-nordisk-071800655.html
The Manufacturers Life Insurance Company Raises Stake in Novo Nordisk A/S $NVO
August 6 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-raises-stake-in-novo-nordisk-as-nvo-2026-08-06/
Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business
August 5 at 10:27 PM  |  msn.comhttps://www.msn.com/en-us/health/other/novo-nordisk-stock-falls-after-raised-forecast-fails-to-change-the-debate-over-its-obesity-business/ar-AA29qeFt
Novo Nordisk Is Exiting a ‘Rough Patch,’ CFO Says. Earnings Prove It.
August 5 at 5:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/m/6d8e7c89-896b-331b-83c2-d09d3c1cd893/novo-nordisk-is-exiting-a.html
Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook
August 5 at 5:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-falls-4-183023765.html
Eli Lilly stock jumps as GLP-1 sales widen Novo lead
August 5 at 5:27 PM  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/33562/eli-lilly-stock-jumps-as-glp-1-sales-widen-novo-lead
Sector Update: Healthcare Stocks Rise Late Afternoon
August 5 at 5:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-rise-afternoon-195004130.html
Lilly climbs, Novo falls as obesity drug battle intensifies
August 5 at 12:26 PM  |  biopharmadive.comB
A New Biopharma Roadmap: Zifo's SiEE Basel Event Puts Data Before AI Hype
August 5 at 12:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biopharma-roadmap-zifos-siee-basel-120000876.html
Eli Lilly and Novo Nordisk raise profit outlook as demand for weight-loss drugs soars
August 5 at 12:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/eli-lilly-novo-nordisk-raise-120141885.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Coastal oil refinery with storage tanks, a gas flare stack, and tankers anchored offshore at dusk.
As the Iran War Resumes, 2 Energy ETFs Ride Oil’s Renewed Rally
By Jessica Mitacek | July 15, 2026
Illustrated data center corridor with server racks and cables leading to a glowing door labeled Anthropic.
Want Anthropic Exposure Before the IPO? These 2 AI Giants Are Already There
By Jessica Mitacek | July 8, 2026
Penguin Solutions logo overlaid on a data center hallway lined with server racks.
Why Penguin Solutions May Be the Smartest AI Infrastructure Stock
By Thomas Hughes | July 8, 2026
AST SpaceMobile logo with a satellite featuring large solar arrays orbiting above Earth in space.
AST SpaceMobile’s Next Launches Could Decide Whether Its Rally Regains Orbit
By Jessica Mitacek | July 13, 2026
Tower Semiconductor logo displayed on a screen with a silicon wafer on a stand in a cleanroom hallway.
Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet
By Jeffrey Neal Johnson | July 15, 2026
Amgen stock logo

Amgen NASDAQ:AMGN

$407.17 +2.32 (+0.57%)
As of 09:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,183.52 -8.42 (-0.71%)
As of 09:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$46.96 +1.00 (+2.16%)
As of 09:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas